Innate Pharma Reports GAAP EPS of -€0.31 with Revenue of €12.35M – Key Insights

Thursday, 12 September 2024, 05:15

Innate Pharma's latest report shows a GAAP EPS of -€0.31 and a revenue of €12.35M. This revenue reflects a significant decrease of 69.3% year-over-year. Investors should focus on understanding the implications of these results on market performance and future opportunities in the sector.
LivaRava_Finance_Default_1.png
Innate Pharma Reports GAAP EPS of -€0.31 with Revenue of €12.35M – Key Insights

Key Financial Results of Innate Pharma

Innate Pharma (IPHA) has recently shared its financial performance for the first half. Below are the highlights:

  • GAAP EPS: -€0.31
  • Revenue: €12.35M
  • Year-over-Year Revenue Change: -69.3%

Implications for Investors

Investors need to evaluate how Innate Pharma's current financial stance may influence stock performance. Factors such as market conditions, upcoming trials, and potential partnerships will play a crucial role in shaping future growth.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe